Keywords: Deuterium, Spectroscopy, Amino acids, Glioblastoma
Motivation: Glioblastoma (GBM) brain tumors are typically detected and demarcated using contrast-enhanced MRI, relying on contrast agent leakage through blood brain barrier (BBB) disruption to define tumor boundaries. However, new amino acid (AA) positron emission tomography (PET) methods have succeeded in detecting tumor cells directly, based on uptake of radiolabeled AA tracers.
Goal(s): Here we were inspired by advances in AA PET and deuterium MRI to measure AA uptake with MRI.
Approach: Using deuterium magnetic resonance spectroscopy, we dynamically quantify deuterated leucine uptake in a rodent model of GBM.
Results: We demonstrate 2H MR measurement of enhanced deuterated leucine uptake in tumoral tissue.
Impact: This proof-of-concept 2H amino acid MR study lays the foundation of a novel, accessible tool to directly image GBM tumors independent of BBB disruption.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords